肿瘤细胞治疗研究
FRONTIER PAPERS
Membrane-Bound Multimodal Plasmonic Transducers for Noninvasive, In Situ Monitoring and Control of CAR T Cells Against Heterogeneous Solid Tumors.
这些换能器在超过 20 mJ cm -2 的激光通量下表现出约 90% 的吸收效率和光稳定性，在多个激光循环中提供光声和热响应。
CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas.
嵌合抗原受体（CAR）T细胞疗法治疗实体瘤的成功有限，部分原因是肿瘤异质性和抗原逃逸。
Chimeric switch scaffold protein augments CAR synapse formation and signaling networks.
这些发现确立了 PLAT 作为一种基于支架的策略，其通过将免疫检查点结合转化为 LAT 依赖的近端信号恢复，直接解决 CAR 固有的信号缺陷。
Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors.
抗原异质性和肿瘤微环境仍是有效CAR-T 细胞疗法的重大障碍，但结合肿瘤内多种抗原及其所处环境的天然配体提供了一种有前景的解决方案。
Harnessing tumor acidity: innovative lactic acid-responsive promoter enables precision control of CAR-T cell activity in solid tumors.
我们的 LARP 策略利用肿瘤酸性作为 CAR-T 细胞的精准低/高开关。
Disulfide-Directed Multicyclic Peptides for Chimeric Antigen Receptors Targeting Solid Tumors.
这些发现共同确立了基于 DDMP 的 CAR 作为一种有前景的框架，用于工程化改造更安全而有效的实体瘤 CAR T 疗法。
IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers.
我们的工作表明，IDR 是通过诱导生物分子凝聚来改善 CAR-T 功能的新工具集。
The future belongs to those who believe in multiplex CAR T engineering.
毒性和免疫逃逸一直阻碍着 CAR T 细胞在 HER2 阳性实体瘤中取得成功。
Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy.
嵌合抗原受体（CAR）T细胞疗法在实体瘤中的应用受到靶向、脱靶毒性、抗原异质性以及无法同时克服肿瘤微环境中多种削弱抗肿瘤活性的耐药机制的制约。
Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity.
嵌合抗原受体（CAR）T 细胞免疫治疗是血液系统恶性肿瘤治疗的突破，但特异性不佳限制了其在实体瘤中的适用性。
MEMBER ACCOUNT
登录成功会直接打开下一页。
